The presentation entitled, " Safety and Efficacy Data from a Phase I Trial of Umbilical Lining Stem Cells (ULSCs) in Adult ...

Cabaletta Bio (CABA) announced new and updated clinical data on CABA-201 demonstrating the potential to achieve drug-free, compelling clinical ...

CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight ...

HC Wainwright reissued their buy rating on shares of Cabaletta Bio (NASDAQ:CABA – Free Report) in a research note published ...

The Company strongly encourages all of its stockholders to read the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the "SEC") on October 18, ...